Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-TP Phase 3 in Glaucoma/OHT
NCT02914509Phase 3Completed
- Sponsor
- Ocular Therapeutix
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing OTX-TP with Placebo (2 arms). Primary endpoint: Mean Intraocular Pressure at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02914509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914509.